Combination of etanidazole with cyclophosphamide and platinum complexes

Beverly A. Teicher, Terence S. Herman, Lawrence Shulman, Glenn Bubley, C. Norman Coleman, Emil Frei

Research output: Contribution to journalArticle

Abstract

In an effort of improve the therapeutic efficacy and selectivity of cyclophosphamide (CTX), cis-diamminedichloroplatinum(II) (CDDP), and carboplatin (Carbo), these antitumor alkylating agents were combined with the 2-nitroimidazole drug etanidazole (ETA). As revealed by tumor-cell survival assay in the FSaIIC murine fibrosarcoma, the addition of ETA (1 g/kg, i.p.) just prior to the i.p. injection of various doses of the alkylating agents resulted in increases in the tumor-cell kill produced by each drug (CTX, 10-fold; CDDP, 20-fold; and Carbo, 5-to 15-fold), whereas toxicity to bone marrow granulocytemacrophage colony-forming units (CFU-GM) increased only about 0- to 3-fold. When CTX was combined with either CDDP or Carbo, striking increases in tumor-cell killing were observed (20- to 100-fold across the CDDP dose range and 5- to 20-fold across the dose range of Carbo), which were supra-additive for CDDP and additive for Carbo as revealed by isobologram analysis. The addition of ETA to these alkylating-agent combinations produced a further approx. 20-fold increase in tumor-cell kill for both CTX/CDDP and CTX/Carbo. This effect was greatest at the lowest dose of the platinum drug tested and was supra-additive in the case of CDDP and additive for Carbo. Following treatment with ETA/CTX/CDDP, bone marrow CFU-GM toxicity increased only about 5-fold over that of CTX/CDDP alone, but the injection of ETA/CTX/Carbo resulted in a 10- to 20-fold increase in bone marrow toxicity as compared with that obtained using CTX/Carbo alone. Tumor growth-delay studies revealed significant increases in the antitumor effect of the alkylating agents when these were given in combination with ETA. Both the ETA/CTX/CDDP and the ETA/CTX/Carbo combinations produced tumor growth delays of 23 days, which represented approx. 1.6-fold increases over those obtained using the alkylating-agent combinations alone. These results suggest that ETA could significantly improve the therapeutic efficacy of these alkylating agents, whether they therapeutic efficacy of these alkylating agents, whether they are given individually or in combination.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume28
Issue number3
DOIs
StatePublished - May 1 1991

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Combination of etanidazole with cyclophosphamide and platinum complexes'. Together they form a unique fingerprint.

  • Cite this

    Teicher, B. A., Herman, T. S., Shulman, L., Bubley, G., Norman Coleman, C., & Frei, E. (1991). Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer Chemotherapy and Pharmacology, 28(3), 153-158. https://doi.org/10.1007/BF00685502